GleamWall
中文EN

ABBV AbbVie Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1551152 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY8.6%
TTM net income YoY-1.2%
TTM EPS YoY-1.3%
Revenue 3-yr CAGR1.8%
Net income 3-yr CAGR-29.1%

Margins

Gross margin70.2%
Operating margin24.6%
Net margin6.9%
FCF margin29.1%
EBITDA margin25.9%

Returns

ROE15,367.3%
ROA3.1%
ROIC (approx.)17.4%
Asset turnover0.45x

Leverage & solvency

Liabilities / assets102.4%
Debt / equity—
Current ratio0.67x
Interest coverage5.21x

Cash quality & payout

Operating cash flow / net income4.50x
Accruals ratio-11.0%
Payout ratio275.8%
Capex / revenue2.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q42025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q42024-12-31
Income statement
Revenue$17.40B$16.99B$15.00B$16.62B$15.78B$15.42B$13.34B$15.10B
Cost of revenue$4.29B$4.29B$4.22B$4.55B$5.30B$4.35B$4.00B$4.40B
Gross profit$13.12B$12.70B$10.78B$12.07B$10.47B$11.08B$9.34B$10.71B
R&D expense$2.57B$2.34B$2.47B$2.58B$2.32B$2.13B$2.07B$6.77B
SG&A expense$4.09B$3.63B$3.58B$3.90B$3.57B$3.25B$3.29B$3.85B
Operating income$6.27B$6.43B$3.99B$4.54B$1.90B$4.89B$3.73B-$1.49B
Interest expense$802.00M$746.00M$717.00M$714.00M$739.00M$740.00M$700.00M$702.00M
Pretax income$4.83B$4.28B$1.04B$2.67B$714.00M$1.55B$1.66B-$2.27B
Income tax$609.00M$662.00M$342.00M$853.00M$526.00M$613.00M$372.00M-$2.25B
Net income$4.22B$3.61B$695.00M$1.82B$186.00M$938.00M$1.29B-$22.00M
EBITDA$6.46B$6.63B$4.18B$4.75B$2.10B$5.08B$3.91B-$1.28B
EPS (basic)2.382.040.391.020.100.520.72-0.02
EPS (diluted)2.372.030.391.020.100.520.72-0.02
Dividends declared per share1.731.731.731.731.641.641.641.64
Weighted avg. shares (diluted)1.77B1.77B1.77B—1.77B1.77B1.77B—
Balance sheet
Cash & equivalents$10.77B$6.57B$9.39B$5.23B$5.63B$6.47B$5.17B$5.52B
Short-term investments———$28.00M$42.00M$0$1.00M$31.00M
Receivables$13.51B$13.82B$12.48B$12.59B$12.77B$12.64B$12.48B$10.92B
Inventory$5.30B$5.13B$5.05B$4.95B$4.94B$4.96B$4.53B$4.18B
Current assets$37.48B$33.67B$33.53B$29.06B$28.54B$29.26B$27.68B$25.58B
PP&E, net$5.94B$5.80B$5.69B$5.63B$5.48B$5.28B$5.24B$5.13B
Goodwill$37.80B$35.52B$35.57B$35.64B$35.63B$35.64B$35.28B$34.96B
Intangibles$56.65B$49.14B$50.87B$52.64B$54.31B$57.03B$58.49B$60.07B
Total assets$147.68B$135.12B$136.46B$133.96B$133.90B$137.18B$136.16B$135.16B
Current liabilities$43.10B$41.64B$42.10B$43.29B$39.39B$39.77B$36.40B$38.75B
Short-term debt$0$0$0$2.50B$3.79B$5.56B$1.59B$0
Long-term debt$72.23B$62.48B$64.53B$58.94B$62.97B$62.96B$64.53B$60.34B
Total debt$72.23B$62.48B$64.53B$61.44B$66.76B$68.52B$66.12B$60.34B
Total liabilities$152.22B$141.00B$143.07B$137.19B$136.50B$137.32B$134.70B$131.80B
Shareholders' equity-$4.58B-$5.93B-$6.66B-$3.27B-$2.64B-$183.00M$1.42B$3.33B
Net debt$61.46B$55.91B$55.14B$56.21B$61.13B$62.05B$60.95B$54.82B
Cash flow statement
Operating cash flow$7.61B$3.44B$3.83B$5.22B$7.02B$5.15B$1.64B$7.05B
Capital expenditure$301.00M$322.00M$265.00M$329.00M$381.00M$269.00M$235.00M$291.00M
Free cash flow$7.30B$3.11B$3.56B$4.89B$6.64B$4.88B$1.40B$6.76B
Investing cash flow-$10.21B-$1.20B-$574.00M-$1.46B-$3.26B-$1.18B-$735.00M-$1.87B
Financing cash flow$6.82B-$5.05B$919.00M-$4.17B-$4.59B-$2.71B-$1.26B-$6.86B
Depreciation & amortization$192.00M$194.00M$188.00M$203.00M$192.00M$186.00M$181.00M$206.00M
Stock-based compensation$160.00M$166.00M$444.00M$157.00M$209.00M$179.00M$410.00M$164.00M
Dividends paid$3.07B$3.07B$3.09B$2.91B$2.91B$2.91B$2.92B$2.75B
Share buybacks$5.00M$9.00M$1.49B$3.00M$4.00M$12.00M$961.00M$358.00M

Free plan shows the latest 8 periods; Pro shows all 59 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.